Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. [PDF]
PLoS ONE, 2013 We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two African populations.ART naïve HIV patients from Ethiopia (n = 285) and Tanzania (n = 209 ...
Eliford Ngaimisi +13 more
doaj +22 more sources
Impact of Efavirenz on Heme Protein Induction and Biomarkers: Insights From In Vitro Experiments and a Clinical Study [PDF]
Clinical and Translational ScienceCoproporphyrin I (CPI) is increasingly recognized as a reliable endogenous biomarker for hepatic OATP1B transporters. However, confounding mechanisms such as increased heme biosynthesis driven by induction of CYP enzymes, which are hemoproteins, may ...
Leila Potzel +5 more
doaj +2 more sources
A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe [PDF]
CPT: Pharmacometrics & Systems PharmacologyEfavirenz induces and inhibits multiple drug‐metabolizing enzymes, contributing to significant drug–drug interactions. This study quantified the impact of multiple doses of efavirenz on CYP3A activity via midazolam metabolism using a population ...
Kimberly S. Collins +6 more
doaj +2 more sources
Efavirenz: History, Development and Future
Biomolecules, 2022 Efavirenz (Sustiva®) is a first-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat human immunodeficiency virus (HIV) type 1 infection or to prevent the spread of HIV.
Bárbara Costa, Nuno Vale
doaj +1 more source
Frontiers in Pharmacology, 2020 Efavirenz-based combination antiretroviral-therapy (cART) is the recommended regimen during tuberculosis (TB) therapy. In a multi-national parallel prospective-cohort study, we investigated the impact of population and pharmacogenetic variations for ...
Sabina Mugusi +11 more
doaj +1 more source
Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz
Biomedicines, 2022 Drug-induced liver injury (DILI) constitutes a clinical challenge due to the incomplete characterization of the mechanisms involved and potential risk factors.
Fernando Alegre +9 more
doaj +1 more source
Therapeutic activities of naringenin on efavirenz-induced sleep-like disorder in the midbrain of white albino mice [PDF]
Iranian Journal of Basic Medical Sciences, 2020 Objective(s): Efavirenz, has proven to be effective in suppressing human immunodeficiency virus (HIV) viral load; however, complaints of sleep disorders including hallucination, and insomnia have greatly contributed to non-adherence to antiretroviral ...
Olufunke Dosumu +3 more
doaj +1 more source
Frontiers in Neurology, 2019 Background: Efavirenz is associated with transient neuropsychiatric manifestations but the impact on neurocognition in children is unknown. Genetically slow metabolizers of efavirenz may be at risk of toxicity.
Charles K. Hammond +4 more
doaj +1 more source
PLoS ONE, 2014 ObjectiveTo assess efavirenz plasma concentrations and their association with treatment efficacy and tolerance of efavirenz 600 mg daily in HIV-tuberculosis co-infected patients.MethodsHIV-infected adults with CD4+ T cell count ≤ 200/mm(3) received ...
Laurence Borand +16 more
doaj +1 more source
Nevirapine versus Efavirenz for patients co-infected with HIV and Tuberculosis: A Randomised Non-Inferiority Trial [PDF]
, 2013 BACKGROUND: In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare efficacy and safety of a nevirapine-
Agnès Sobry +39 more
core +3 more sources